Inactive Instrument

Highlights Verona Pharma Plc London S.E.

Equities

GB00B06GSH43

End-of-day quote London S.E. Other stock markets
- ^GBX	-

05-13	HC Wainwright Adjusts Price Target on Verona Pharma to $30 From $32, Maintains Buy Rating	MT
05-09	Verona Pharma Signs Financing Agreements for Up to $650 Million	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Verona Pharma Signs Financing Agreements for Up to $650 Million	05-09	MT
Verona Pharma Shares Decline After Q1 Loss Widens	05-09	MT
Verona Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	05-06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	05-03	MT
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024	05-02	CI
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	04-16	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	04-05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	04-04	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	03-25	MT
Verona Pharma Shares Rise After Narrower-Than-Expected Q4 Loss	02-29	MT
Verona Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Verona Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
FTSE 100 Ends Week Down, Dragged by Oil Majors	02-02	DJ
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Traders Exercise Caution	01-02	MT
Verona Pharma plc Reports Earnings Results for the Third Quarter Ended September 30, 2023	11-02	CI
Verona Pharma plc Announces U.S. Food and Drug Administration Accepts for Review the Company's New Drug Application for Esifentrine for the Maintenance Treatment of Patients with Chronic Obstructive Pulmonary Disease	11/09/23	CI
Verona Pharma plc Reports Earnings Results for the Second Quarter Ended June 30, 2023	03/08/23	CI
Verona Pharma Files NDA for COPD; Wedbush Sees Strong Probability of Acceptance; Shares Gain Premarket	28/06/23	MT
Verona Pharma Files NDA in US for Maintenance Treatment of COPD; Wedbush Sees Strong Probability of Acceptance	28/06/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Verona Pharma Plc London S.E.

Equities

GB00B06GSH43

Highlights

Filters